Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CUMBERLAND PHARMACEUTICALS INC
Report date March 17, 2022 · Filed April 29, 2022
Section 16 reporting ended · disclosed 2022-04-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 163,473 |
Reported balance
After 2022-03-17 transaction · row 1
1 source rowRow 1 · 2022-03-17 · Other · Disposed 15,000 · Balance 163,473 F1: Mr. Cearnal passed away on March 17, 2022. All unvested equity awards forfeited upon death. |
| Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2031-03-17 | Direct | 0 |
Reported balance
After 2022-03-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-17 · Other · Disposed 5,000 · Balance 0 F1: Mr. Cearnal passed away on March 17, 2022. All unvested equity awards forfeited upon death. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Cearnal passed away on March 17, 2022. All unvested equity awards forfeited upon death.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.83 | $297.15 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 2 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,009 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 18, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.91 | $305.55 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 1 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,904 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 17, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 5,700 | $2.83 | $16,131.00 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 25 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,799 F4 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.805 to $2.8797, inclusive. Read SEC document |
| May 17, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.84 | $298.20 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 24 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,099 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 14, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 5,000 | $2.77 | $13,850.00 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 23 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,994 F3 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.715 to $2.792, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4. Read SEC document |
| May 14, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.81 | $295.05 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 22 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,994 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 13, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.88 | $302.40 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 21 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,889 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 12, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.86 | $300.30 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 20 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,784 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 11, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.68 | $281.40 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 19 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,679 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 10, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.71 | $284.55 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 18 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,574 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 07, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.73 | $286.65 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 17 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,469 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 06, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.74 | $287.70 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 16 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,364 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 05, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.73 | $286.65 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 15 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,259 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 04, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.66 | $279.30 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 14 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,154 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 03, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.66 | $279.30 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 13 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,049 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| April 30, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.78 | $291.90 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 12 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,944 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| April 29, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.89 | $303.45 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 11 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,839 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| April 28, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 80 | $2.94 | $235.20 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 10 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,734 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| April 27, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.94 | $308.70 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 9 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,654 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| April 26, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.97 | $311.85 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 8 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,549 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| April 23, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.99 | $313.95 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 7 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,444 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| April 22, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.96 | $310.80 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 6 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,339 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| April 21, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.97 | $311.85 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 5 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,234 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| April 20, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.02 | $317.10 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 4 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,129 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| April 19, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.04 | $319.20 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 3 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,024 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| April 16, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.03 | $318.15 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 2 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,919 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| March 17, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantOptions (right to buy) · Derivative | 5,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · derivative · entry 26 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2031-03-17 F5 · shares: 100% vesting on March 17, 2025. Read SEC document |
| March 17, 2021 Filed Jun 8, 2021 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Tax withholdingCommon Stock | 2,945 | $3.22 | $9,482.90 |
DisclosureSEC source: 0001209191-21-038980 · doc4.xml · nonDerivative · entry 1 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,814 F1 · shares: This transaction represents shares withheld/purchased by the Company to cover the tax withholding obligations for the vesting of shares. Read SEC document |
| March 23, 2020 Filed Apr 17, 2020 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 5,000 | $3.56 | $17,800.00 |
DisclosureSEC source: 0001209191-20-024876 · doc4.xml · nonDerivative · entry 2 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,759 F2 · shares: Restricted stock award will vest 100% on March 23, 2024. Read SEC document |
| March 18, 2020 Filed Apr 17, 2020 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Tax withholdingCommon Stock | 1,186 | $3.53 | $4,186.58 |
DisclosureSEC source: 0001209191-20-024876 · doc4.xml · nonDerivative · entry 1 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,759 F1 · shares: This transaction represents shares withheld/purchased by the Company to cover the tax withholding obligations for the vesting of shares. Read SEC document |
| November 26, 2019 Filed Nov 29, 2019 22:25 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Tax withholdingCommon Stock | 472 | $4.93 | $2,326.96 |
DisclosureSEC source: 0001209191-19-058441 · doc4.xml · nonDerivative · entry 1 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,945 F1 · shares: This transaction represents shares withheld/purchased by the Company to cover the tax withholding obligations for the vesting of shares. Read SEC document |
| March 22, 2019 Filed Mar 22, 2019 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Tax withholdingCommon Stock | 1,250 | $5.62 | $7,025.00 |
DisclosureSEC source: 0001209191-19-021050 · doc4.xml · nonDerivative · entry 2 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,417 F2 · shares: This transaction represents shares withheld/purchased by the Company to cover the tax withholding obligations for the vesting of shares. Read SEC document |
| March 22, 2019 Filed Mar 22, 2019 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 5,000 | $5.98 | $29,900.00 |
DisclosureSEC source: 0001209191-19-021050 · doc4.xml · nonDerivative · entry 1 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,667 F1 · shares: Restricted stock award will vest 100% on March 18, 2023. Read SEC document |
| March 23, 2018 Filed Mar 23, 2018 21:46 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Tax withholdingCommon Stock | 890 | $6.70 | $5,963.00 |
DisclosureSEC source: 0001209191-18-021485 · doc4.xml · nonDerivative · entry 2 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,667 F2 · shares: This transaction represents shares withheld/purchased by the Company to cover the tax withholding obligations for the vesting of shares. Read SEC document |
| March 23, 2018 Filed Mar 23, 2018 21:46 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 5,000 | $6.70 | $33,500.00 |
DisclosureSEC source: 0001209191-18-021485 · doc4.xml · nonDerivative · entry 1 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,557 F1 · shares: Restricted stock award will vest 100% on March 20, 2022. Read SEC document |
| April 07, 2017 Filed Apr 7, 2017 21:00 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Tax withholdingCommon Stock | 1,959 | $6.45 | $12,635.55 |
DisclosureSEC source: 0001209191-17-026310 · doc4.xml · nonDerivative · entry 2 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,557 F2 · shares: This transaction represents shares withheld by the Company to cover the tax withholding obligations for the vesting of 6,000 shares during March 2017. Read SEC document |
| April 07, 2017 Filed Apr 7, 2017 21:00 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 11,600 | $6.45 | $74,820.00 |
DisclosureSEC source: 0001209191-17-026310 · doc4.xml · nonDerivative · entry 1 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,516 F1 · shares: Restricted stock award will vest 100% on March 17, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.